Department of Pharmacology, New Drug Discovery Research, Ranbaxy Research Laboratories, Plot No. 20, Sector 18, Udyog Vihar, Gurgaon, 122015, Haryana, India.
Expert Opin Investig Drugs. 2010 Apr;19(4):455-68. doi: 10.1517/13543781003643486.
Millions of people suffer from neuropathic pain (NP), but the treatment is empirical and results in transient relief in only a few patients. This is primarily because of the poor understanding of the molecular mechanism underlying NP. Following nerve injury, there is a differential and temporal pattern of MMPs expression that coincides with changes in levels of pro-inflammatory cytokines, suggesting that MMPs not only act as mediators for neuroinflammation but might also be directly involved in pain associated with nerve damage.
The present review describes the different mechanisms of NP. The main focus of the review is to highlight the importance of MMPs in NP and their inhibition as a novel approach for treating NP.
A comprehensive overview of the role of MMPs in the pathogenesis of NP and the potential of MMP inhibition as a therapeutic intervention for NP.
Targeted therapy using specific MMP inhibitors, siRNAs, peptide inhibitors and monoclonal antibodies can provide a better way of treatment by blocking a single MMP and can reduce the side effects of broad-spectrum MMP inhibitors.
数以百万计的人患有神经性疼痛（NP），但治疗是经验性的，只有少数患者有短暂的缓解。这主要是因为对 NP 潜在分子机制的了解不足。在神经损伤后，MMPs 的表达呈现出不同的、时间性的模式，与促炎细胞因子水平的变化相一致，这表明 MMPs 不仅作为神经炎症的介质起作用，而且可能直接参与与神经损伤相关的疼痛。
本篇综述描述了 NP 的不同机制。综述的主要重点是强调 MMPs 在 NP 中的重要性及其抑制作用作为治疗 NP 的一种新方法。
对 MMPs 在 NP 发病机制中的作用以及 MMP 抑制作为 NP 治疗干预的潜力的全面概述。
使用特定的 MMP 抑制剂、siRNA、肽抑制剂和单克隆抗体的靶向治疗可以通过阻断单个 MMP 提供更好的治疗方法，并减少广谱 MMP 抑制剂的副作用。
